Background

Mean-field game (MFG) theory models large populations of rational agents interacting through aggregate population-level effects. In immunology, lymphocyte populations (Tregs, Th17, B-cells, macrophages) continuously adjust their activation, proliferation, and migration strategies in response to the aggregate cytokine milieu — a natural MFG framework. Loss of peripheral tolerance in rheumatoid arthritis (RA) can be conceptualized as the breakdown of a Nash equilibrium in this immune MFG, where no cell population has incentive to deviate from homeostatic behavior.

Hypothesis

We hypothesize that modeling serial immunophenotyping and cytokine panel data as a coupled Hamilton-Jacobi-Bellman / Fokker-Planck (HJB-FP) system — the canonical MFG formulation — will reveal that preclinical RA exhibits measurable departure from Nash equilibrium in the immune cell population game 6–18 months before seroconversion or clinical symptom onset. Specifically:

1. Equilibrium deviation index (EDI): A scalar metric quantifying the L² distance between observed immune population distributions and the MFG Nash equilibrium solution will exceed a critical threshold (EDI > τ_crit) in individuals destined to develop RA, while remaining stable in matched controls.

2. Treg-Th17 strategic imbalance: The MFG cost functional for Treg populations will show increasing values (higher "cost" of maintaining suppressive strategy), reflecting the energetic unsustainability of tolerance maintenance in the preclinical inflammatory milieu.

3. Bifurcation prediction: The MFG system will exhibit a saddle-node bifurcation structure where the tolerogenic Nash equilibrium and a pro-inflammatory equilibrium coalesce and annihilate, providing a mathematically rigorous prediction of the irreversible transition to autoimmunity.

Proposed Methodology

• Cohort: Leverage existing at-risk cohorts (ACPA+ asymptomatic first-degree relatives of RA patients, n ≥ 200) with serial immunophenotyping (CyTOF, 30+ markers) and multiplex cytokine panels (≥ 40 analytes) at 3-month intervals over 3 years.
• MFG formulation: Define N = 6 interacting cell populations (naïve T, Th1, Th17, Treg, B-cell, monocyte/macrophage) with state variables (activation, proliferation, cytokine secretion rates). Each population optimizes a cost functional balancing survival/proliferation benefits against energy expenditure and cytokine-mediated penalties from other populations.
• Numerical solution: Solve the coupled HJB-FP system using finite-difference schemes on the population density space, with pharmacogenomic HLA-DRB1 shared epitope status as a parameter modulating the cost functional landscape.
• Validation: Compare EDI trajectory AUC-ROC for predicting clinical RA onset against standard biomarkers (ACPA titer, RF, CRP, IL-6).

Testable Predictions

1. EDI will achieve AUC > 0.85 for predicting RA onset within 18 months, outperforming ACPA titer alone (expected AUC ~0.70).
2. The saddle-node bifurcation parameter (cytokine milieu intensity) will correlate with HLA-DRB1 shared epitope dose (0, 1, or 2 copies), with double-dose carriers showing lower bifurcation thresholds.
3. Pharmacogenomic CTLA-4 and PTPN22 risk alleles will shift the Treg cost functional, quantifiably lowering the Nash equilibrium stability margin.
4. Therapeutic intervention with abatacept (CTLA-4-Ig) in preclinical RA will measurably restore EDI toward equilibrium, providing a pharmacodynamic biomarker for prevention trials.

Limitations

• MFG theory assumes a continuum approximation of cell populations; rare cell types or small populations may violate mean-field assumptions and require finite-player game corrections.
• The HJB-FP system is computationally expensive to solve in high dimensions; practical implementation may require neural network approximations (DeepMFG) with associated approximation error.
• Immunophenotyping resolution at 3-month intervals may miss rapid equilibrium transitions; higher-frequency sampling in a subset would be needed to validate temporal dynamics.
• The rational agent assumption in MFG is a modeling abstraction — immune cells do not literally optimize cost functionals, but evolutionary dynamics produce behavior well-approximated by this framework.
• Cohort sizes for at-risk populations are inherently limited, and external validation across diverse genetic backgrounds is essential before clinical translation.

Clinical Significance

If validated, the MFG-derived EDI would represent a fundamentally new class of biomarker — one grounded in game-theoretic equilibrium analysis rather than individual molecular concentrations. This could enable:

• Precision prevention: Identifying the exact window where tolerance breakdown becomes irreversible, optimizing timing for preventive intervention.
• Pharmacodynamic monitoring: Using EDI as a composite endpoint in RA prevention trials, potentially reducing required sample sizes by capturing the systems-level treatment effect.
• Mechanistic insight: The cost functional landscape provides interpretable information about why tolerance fails in specific patients, linking pharmacogenomic risk to quantifiable strategic disadvantage in the immune cell game.

This framework extends naturally to other autoimmune diseases where loss of tolerance is the fundamental event, and could integrate with DeSci federated computation infrastructure to enable multi-center MFG model fitting without sharing raw patient-level immunophenotyping data.

RheumaAI Research • rheumai.xyz • DeSci Rheumatology